{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:45Z","timestamp":1785909165388,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Severe\n                      <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n                      pneumonia (SMPP) in children can lead to pulmonary function impairment. This study aimed to evaluate the impact of early corticosteroid therapy combined with antibiotics versus antibiotics alone on short-term pulmonary function and clinical outcomes in children diagnosed with SMPP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was performed on 259 pediatric inpatients diagnosed with SMPP at our hospital between October 2022 and June 2025. Patients were divided into the antibiotics alone group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009158) and the early corticosteroid use group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009101). Pulmonary function, such as peak expiratory flow (PEF), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and small airway function parameters were measured before and after treatment. We also assessed injury markers\u2014including lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)\u2014as well as inflammatory cytokines (C-reactive protein [CRP], interleukin-6 [IL-6], and interferon-gamma [IFN-\u03b3]) and immunoglobulins (IgA, IgG, IgM). Clinical symptom resolution times and adverse reactions were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After treatment, the early corticosteroid group showed significantly higher PEF (5.74\u2009\u00b1\u20090.57 vs. 5.13\u2009\u00b1\u20090.65 L\/s), FEV1 (2.81\u2009\u00b1\u20090.35 vs. 2.38\u2009\u00b1\u20090.33 L), and FVC (3.22\u2009\u00b1\u20090.44 vs. 2.75\u2009\u00b1\u20090.41 L), along with better small airway function compared to the antibiotics alone group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). The corticosteroid group also exhibited notably lower levels of LDH (398.62\u2009\u00b1\u2009105.43 vs. 492.36\u2009\u00b1\u2009118.74 U\/L), CRP (7.62\u2009\u00b1\u20092.14 vs. 12.35\u2009\u00b1\u20093.28\u2005mg\/L), and IL-6 (14.28\u2009\u00b1\u20094.53 vs. 24.51\u2009\u00b1\u20096.75 pg\/mL), and higher immunoglobulin levels (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Times to cough disappearance, defervescence, and hospitalization were notably shorter in the corticosteroid group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early corticosteroid use combined with antibiotics was associated with significantly greater short-term improvement in pulmonary function, reduced inflammatory markers, and faster clinical symptom resolution in children with SMPP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1867429","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:41:28Z","timestamp":1785908488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severe Mycoplasma pneumoniae pneumonia"],"prefix":"10.3389","volume":"14","author":[{"given":"Mingyu","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Chengdu Shuangliu Hospital of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chengdu Shuangliu Hospital of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chengdu Shuangliu Hospital of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yuxi Zhongshan Hospital","place":["Yuxi, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Lincang People\u2019s Hospital","place":["Lincang, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12879-024-09340-x","article-title":"A comparative study of general and severe Mycoplasma pneumoniae pneumonia in children","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/QCO.0000000000001126","article-title":"Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities","volume":"38","author":"De Groot","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ped4.70014","article-title":"Low-dose versus high-dose methylprednisolone for children with severe Mycoplasma pneumoniae pneumonia (MCMP): a randomized controlled trial","volume":"9","author":"Xu","year":"2025","journal-title":"Pediatr Investig"},{"key":"B4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.29271\/jcpsp.2020.03.268","article-title":"Changes and significance of serum sB7-H3 and cytokines in children with Mycoplasma pneumonae pneumonia","volume":"30","author":"Wu","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"B5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12931-025-03189-7","article-title":"Immunological landscape of children with Mycoplasma pneumoniae pneumonia in the post-COVID-19 era reveals distinctive severity indicators","volume":"26","author":"Jia","year":"2025","journal-title":"Respir Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2666-5247(23)00344-0","article-title":"Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions","volume":"5","author":"Meyer Sauteur","year":"2024","journal-title":"Lancet Microbe"},{"key":"B7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12879-024-09564-x","article-title":"Azithromycin sequential therapy plus inhaled terbutaline for Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis","volume":"24","author":"Sheng","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1437475","DOI":"10.3389\/fphar.2024.1437475","article-title":"Yinqin Qingfei granules alleviate Mycoplasma pneumoniae pneumonia via inhibiting NLRP3 inflammasome-mediated macrophage pyroptosis","volume":"15","author":"Song","year":"2024","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1427702","DOI":"10.3389\/fmicb.2024.1427702","article-title":"An outbreak of Mycoplasma pneumoniae in children after the COVID-19 pandemic, Shanghai, China, 2023","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Microbiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1135228","DOI":"10.3389\/fcimb.2023.1135228","article-title":"Clinical features and \u201cearly\u201d corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ped4.12469","article-title":"Evidence-based guideline for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023)","volume":"9","year":"2025","journal-title":"Pediatr Investig"},{"key":"B12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3947\/ic.2014.46.4.239","article-title":"Early additional immune-modulators for Mycoplasma pneumoniae pneumonia in children: an observation study","volume":"46","author":"Youn","year":"2014","journal-title":"Infect Chemother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/jcm8050726","article-title":"Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children","volume":"8","author":"Yang","year":"2019","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm11102824","article-title":"Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management","volume":"11","author":"Tong","year":"2022","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3760\/cma.j.cn112140-20240722-00503","article-title":"[Evidence-based guideline for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023)]","volume":"62","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B16","first-page":"745","article-title":"Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association, Editorial Board, Chinese Journal of Pediatrics. [Guidelines for management of community acquired pneumonia in children (the revised edition of 2013) (I)]","volume":"51","year":"2013","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1002\/iid3.849","article-title":"Analysis of cytokine levels, cytological findings, and MP-DNA level in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia","volume":"11","author":"Deng","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/crj.13620","article-title":"Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children","volume":"17","author":"Fan","year":"2023","journal-title":"Clin Respir J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/ppul.26593","article-title":"Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood: a retrospective study","volume":"58","author":"Luo","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4168\/aair.2014.6.1.22","article-title":"Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children","volume":"6","author":"You","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12931-024-02892-1","article-title":"The role of LDH and ferritin levels as biomarkers for corticosteroid dosage in children with refractory Mycoplasma pneumoniae pneumonia","volume":"25","author":"Wei","year":"2024","journal-title":"Respir Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e39665","DOI":"10.1097\/MD.0000000000039665","article-title":"Prospective cohort study on the clinical significance of interferon-\u03b3, D-dimer, LDH, and CRP tests in children with severe mycoplasma pneumonia","volume":"103","author":"Zhang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00431-024-05519-1","article-title":"Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia","volume":"183","author":"Ding","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"897550","DOI":"10.3389\/fsurg.2022.897550","article-title":"Pediatric critical illness score, clinical characteristics and comprehensive treatment of children with severe Mycoplasma pneumoniae pneumonia","volume":"9","author":"Fang","year":"2022","journal-title":"Front Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e075835","DOI":"10.1136\/bmj-2023-075835","article-title":"Association between antenatal corticosteroids and risk of serious infection in children: nationwide cohort study","volume":"382","author":"Yao","year":"2023","journal-title":"Br Med J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s12879-024-10090-z","article-title":"COVID-19 severity and corticosteroid treatment have minimal effect on specific antibody production","volume":"24","author":"Nakamoto","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e20778","DOI":"10.1016\/j.heliyon.2023.e20778","article-title":"The dysfunction of Tfh cells promotes pediatric recurrent respiratory tract infections development by interfering humoral immune responses","volume":"9","author":"Diao","year":"2023","journal-title":"Heliyon"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.29063\/ajrh2025\/v29i5s.13","article-title":"Clinical impact of bronchoscopy combined with targeted nursing of oxygen nebulization inhalation in pediatric mycoplasma lobar pneumonia","volume":"29","author":"Cai","year":"2025","journal-title":"Afr J Reprod Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10238-025-01793-x","article-title":"Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients","volume":"25","author":"Zhao","year":"2025","journal-title":"Clin Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000005106","article-title":"Systemic corticosteroids in children with pneumonia: a systematic review and meta-analysis","author":"Geropeppa","year":"2025","journal-title":"Pediatr Infect Dis J"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1867429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:41:30Z","timestamp":1785908490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1867429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":31,"alternative-id":["10.3389\/fped.2026.1867429"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1867429","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1867429"}}